The Effect of Botulinum Toxin on the Amount of Sialorrhea in Patients With Neurologic Diseases

Background: Drooling is an annoying problem in some neurologic and systemic diseases. Injecting botulinum toxin in the salivary glands is one of the most effective and safest treatments. Objectives: This study was conducted to evaluate the effect of botulinum toxin on the amount of sialorrhea in patients with neurologic diseases. Materials and methods: This study included ten patients and 60 units of botulinum toxin type A (Dysport) were injected in any submandibular gland and 120 units were injected in any parotid gland bilaterally under the ultrasonographic guide. To check drooling, daily consumption of tissue was counted and it was cheeked once before injection and at six, 12, 18, and 24 weeks after injection; then the results were compared. Results: In this study, the effect of Dysport on the amount of drooling of the participants at the sixth, 12th, and 18th weeks after treatment was significantly decreased (P value of 0.00016, 0.0001, and 0.00011, respectively). However, after 24 weeks, this difference was not significant (P value = 0.15). Conclusions: These finding showed that Dysport can be significantly effective in reducing the amount of saliva for 18 weeks.

[1]  L. Laccourreye,et al.  Ultrasound-guided botulinum toxin injections for treatment of drooling. , 2011, European annals of otorhinolaryngology, head and neck diseases.

[2]  J. van Limbeek,et al.  Efficacy and duration of botulinum toxin treatment for drooling in 131 children. , 2010, Archives of otolaryngology--head & neck surgery.

[3]  M. Inghilleri,et al.  Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: A clinical and neurophysiological study , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[4]  A. Merati,et al.  Prevalence of dysplasia in juvenile-onset recurrent respiratory papillomatosis. , 2010, Archives of otolaryngology--head & neck surgery.

[5]  M. Swash,et al.  Association of paraspinal and diaphragm denervation in ALS , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[6]  M. de Carvalho,et al.  Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis , 2008, Journal of Neurology.

[7]  P. Dawes,et al.  Botulinum toxin type-A (Botox-A) injections for treatment of sialorrhoea in adults: a New Zealand study. , 2006, The New Zealand medical journal.

[8]  M. Naumann,et al.  Botulinum toxin treatment of secretory disorders , 2004, Movement disorders : official journal of the Movement Disorder Society.

[9]  F. J. C. Artal Tratamiento de la sialorrea en enfermedades neurológicas mediante inyecciones transcutáneas de toxina botulínica A en las glándulas parótidas , 2003 .

[10]  E. Tan,et al.  Emerging therapeutic applications of botulinum toxin. , 2003, Medical science monitor : international medical journal of experimental and clinical research.

[11]  K. Bushara Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment--botulinum toxin A injections of the parotid glands. , 1997, Medical hypotheses.

[12]  R. Lazar,et al.  The current management of sialorrhea. , 1991, Ear, nose, & throat journal.

[13]  S. Ra,et al.  Current concepts: sialorrhea. , 1970 .

[14]  F. C. Carod Artal [Treatment of sialorrhoea in neurological diseases with trans-dermic injections of botulinum toxin type A in the parotid glands]. , 2003, Neurología.

[15]  R. Goode,et al.  Current concepts: sialorrhea. , 1970, New England Journal of Medicine.